Clinical trial · Observational
Registry Study for Talimogene Laherparepvec
A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or BioVEX-Sponsored Clinical Trials
NCT02173171CI-TRIAL-00054198completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or BioVEX-Sponsored Clinical Trials
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial | Melanoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Information collection | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Previously treated with T-VEC
- description
- Received at least 1 dose of talimogene laherparepvec on Amgen or BioVEX-sponsored clinical trial
- interventionNames
- Other: Information collection
Primary outcomes (3)
- measure
- Talimogene Laherparepvec Related Adverse Events
- timeFrame
- 7 years
- description
- Long-term safety of talimogene laherparepvec will be assessed by reporting of related adverse events every 3 months. Related serious adverse events will be reported within 24 hours following investigator's knowledge of the event.
- measure
- Subject overall survival
- timeFrame
- 7 years
- description
- Overall survival status will be reported every 3 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: All subjects must provide informed consent prior to initiation of any study activities. All subjects must have received at least one dose of talimogene laherparepvec on an Amgen or BioVEX-sponsored clinical trial for any tumor type and must have discontinued treatment and participation, including long-term follow-up (if applicable) in that trial. Exclusion Criteria: Subjects currently receiving talimogene laherparepvec in Amgen or BioVEX-sponsored clinical trial. Subject currently participating, including for long-term follow-up (if applicable), in other Amgen-sponsored talimogene laherparepvec clinical trial.
References
Publications (0)
Data not yet available
No reference posted for this study.